Impaired proliferation and differentiation of myelodysplastic CD34+ cells.

Abstract:

:The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders of hematopoiesis entailing hyperproliferative and ineffective hematopoiesis resulting in refractory cytopenia(s), and increased risk of transformation into acute myeloblastic leukemia (AML). The widely used classification defined by the French-American-British group (FAB) recognizes 5 cytological subtypes of different prognosis, based essentially on the presence and the frequency of marrow blasts. The percentage of marrow blasts does not exceed 30%, hence, direct investigations of biological and biochemical events of MDS blast cells have been hampered. The CD34 antigen is currently unique in its narrow specificity of expression on human lymphohematopoietic progenitor cells. This cell membrane phosphoglycoprotein has been used for immunologic blast cell purification, notwithstanding the frequency of marrow blasts, and has provided a set of tools for investigations of MDS i.e. a direct comparison of the nature of blast cells in each of the MDS subtypes, using immunologic, biologic, biochemical and molecular biological methodology. A combination of serum-free medium and a purification method for blast cells provided evidence that the progenitor cell growth abnormalities in these disorders involve a defect in the capacity of progenitor cells to respond to stimulation with growth factor(s), and has presented direct evidence for the manner in which myelodysplastic CD34+ cells are impaired.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Sawada K

doi

10.3109/10428199409049649

subject

Has Abstract

pub_date

1994-06-01 00:00:00

pages

37-47

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

14

pub_type

杂志文章,评审
  • Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia.

    abstract::We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or supportive care alone (19%). Median and 4-year overall survival (OS)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1637865

    authors: Kuzich JA,Hutchison AP,Lim KJC,Smallbone P,Denning K,Wright MP,Cull G,Leahy MF,Joske DJL,Radeski D,Purtill D

    更新日期:2019-12-01 00:00:00

  • Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

    abstract::To assess the efficacy of haploidentical hematopoietic stem cell transplantation (HSCT) in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), we retrospectively analyzed 30 cases that presented at our institution. At the time of HSCT, 20 patients (66.7%) had achieved a resp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1330467

    authors: Li Z,Wang Y,Wang J,Zhang J,Wang Z

    更新日期:2018-01-01 00:00:00

  • Up-regulation of tissue inhibitor of metalloproteinase-2 promotes SHI-1 cell invasion in nude mice.

    abstract::The role of tissue inhibitor of metalloproteinase-2 (TIMP-2) in extramedullary infiltration of acute leukemia is unclear. We demonstrated in our previous study that the up-regulation of TIMP-2 promoted SHI-1 cell invasion in vitro. We investigated in the present study whether TIMP-2 would have the same effect in vivo....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.783214

    authors: Wang C,Cai X,Chen B,He Z,Chen Z,Cen J,Li Z

    更新日期:2013-12-01 00:00:00

  • The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML).

    abstract::Immune mechanisms superimposed to the myeloablative conditioning regimens exert an additional powerful effect in eradicating leukemia and in achieving immunological control of minimal residual disease. The impact of GVHD-independent GVL has been evaluated to be absent, or near absent, in ALL, about 30% in AML and abou...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309047890

    authors: Marmont AM

    更新日期:1993-01-01 00:00:00

  • CD1d expression as a prognostic marker for chronic lymphocytic leukemia.

    abstract::We analyzed the expression of CD1d, an antigen-presenting molecule, on peripheral blood leukemic cells of cases of chronic lymphocytic leukemia (CLL) by flow cytometry. We demonstrated variable expression of CD1d on leukemic lymphocytes and an association between high expression of CD1d with shorter time to treatment ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.803222

    authors: Anastasiadis A,Kotsianidis I,Papadopoulos V,Spanoudakis E,Margaritis D,Christoforidou A,Gouliamtzi S,Tsatalas C

    更新日期:2014-02-01 00:00:00

  • Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures.

    abstract::EBER in situ hybridization (EBER) and LMP-1 immunohistochemistry (LMP-1) are widely used for identifying Epstein-Barr virus (EBV) within tumor cells of Hodgkin lymphoma (HL), but measurement error has never been formally evaluated. To determine assay reliability, 40 HL tumors with known EBV status were stained for bot...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819032000141310

    authors: Glaser SL,Gulley ML,Borowitz MJ,Craig FE,Mann RB,Stewart SL,Shema SJ,Ambinder RF

    更新日期:2004-03-01 00:00:00

  • Acute myeloid leukemia risk by industry and occupation.

    abstract::Acute myeloid leukemia (AML) is the most common type of leukemia found in adults. Identifying jobs that pose a risk for AML may be useful for identifying new risk factors. A matched case-control analysis was conducted using California Cancer Registry data from 1988 to 2007. This study included 8999 cases of AML and 24...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.894189

    authors: Tsai RJ,Luckhaupt SE,Schumacher P,Cress RD,Deapen DM,Calvert GM

    更新日期:2014-11-01 00:00:00

  • The Wilms tumour gene WT1 in leukaemia.

    abstract::The WT1 gene is essential for kidney development and is mutated in some Wilms tumours. It is also expressed at a high level in many acute leukaemias and in some haematopoietic progenitor cells, and mutations have been found in leukaemias. The function of WT1, which is a zinc finger protein and has domains characterist...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709059677

    authors: Pritchard-Jones K,King-Underwood L

    更新日期:1997-10-01 00:00:00

  • Shedding of CD9 antigen in acute lymphoblastic leukemia.

    abstract::A leukemia-associated CD9 glycoprotein antigen released into the extracellular milieu from acute lymphoblastic leukemia cells has been detected using a unique lectin-monoclonal antibody immunoassay. It has been demonstrated that the release of CD9 antigen is an active process and is associated with active cell growth....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409073777

    authors: Komada Y,Sakurai M

    更新日期:1994-02-01 00:00:00

  • Cell cycle-independent down-regulation of BCL-2 protein expression in differentiating HL-60 cells.

    abstract::To understand the relationship between bcl-2 protein expression and the cell cycle during the processes of differentiation, we examined bcl-2 protein levels expressed during cell cycle phases in differentiating HL-60 human leukemia cells by using a two-color flow cytometric method. In exponentially proliferating HL-60...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009148859

    authors: Kumakura S,Ishikura H,Tsumura H,Nakashima A,Sato Y,Kobayashi S

    更新日期:2000-01-01 00:00:00

  • Extranodal adult T-cell leukemia/lymphoma of the head and neck: a clinicopathological study of nine cases and a review of the literature.

    abstract::Extranodal adult T-cell leukemia/lymphoma (ATLL) of the head and neck is a rare disease. We studied the clinicopathological features of nine patients with ATLL involving extranodal head and neck sites and conducted a literature review. Six patients presented with extranodal mass of the head and neck, whereas three had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802702383

    authors: Miyagi T,Nagasaki A,Taira T,Shinhama A,Suzuki M,Ohshima K,Takasu N

    更新日期:2009-02-01 00:00:00

  • Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.

    abstract::Chemotherapy has long been integral to the treatment of chronic lymphocytic leukemia (CLL). Fludarabine/cyclophosphamide, chlorambucil and bendamustine are commonly used as a backbone, depending on the patient's age and general health. The advent of the anti-CD20 monoclonal antibodies, such as rituximab and obinutuzum...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1330474

    authors: Wendtner CM,Gregor M

    更新日期:2018-02-01 00:00:00

  • Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is characterized by profound immune dysfunction and a marked resistance to apoptosis. Understanding the cellular biology of immune effector cells from CLL patients as well as leukemic target cells is essential to developing immune mediated therapeutic strategies for CLL. In th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009113387

    authors: Vu UE,Pavletic ZS,Wang X,Joshi SS

    更新日期:2000-11-01 00:00:00

  • A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.

    abstract::Clonal bone marrow (BM) B-cell populations are a common finding in patients with suspected primary central nervous system lymphoma (PCNSL). To assess their clinical significance, benign monoclonal B-cell lymphocytosis (MBL) needs to be differentiated from concomitant BM involvement, since patients with secondary centr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1482538

    authors: Brandt A,Matschke J,Fehrle W,von Wenserski L,Bokemeyer C,Illerhaus G,Binder M

    更新日期:2019-02-01 00:00:00

  • Non-Hodgkin's lymphoma and pregnancy.

    abstract::Non-Hodgkin's lymphoma (NHL) is infrequently diagnosed during pregnancy. Most NHL's complicating pregnancy are aggressive and disseminated. This presentation together with the possible teratogenecity of diagnostic methods dictate a limited staging workup during pregnancy. Although prognosis had been reported to be poo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409049697

    authors: Lishner M,Zemlickis D,Sutcliffe SB,Koren G

    更新日期:1994-08-01 00:00:00

  • The insulin-like growth factor system in hematopoietic cells.

    abstract::The insulin-like growth factor (IGF) system regulates proliferation and differentiation of hematopoietic cells. IGFs exert their effects through specific receptors on growing and differentiating blood cells as they emerge from their small pool of ancestral stem cells. The IGF system is complex as both stimulating and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290011958

    authors: Zumkeller W

    更新日期:2002-03-01 00:00:00

  • Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome.

    abstract::To evaluate its clinical efficacy as well as its biologic safety, human recombinant Erythropoietin (rh-Epo) was given to 19 patients with myelodysplastic syndromes (MDS) in an open non-randomized study. Among the seventeen evaluable patients only two showed an apparent hematologic response to rh-Epo treatment. In thes...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309147366

    authors: Razzano M,Caslini C,Cortelazzo S,Battistel V,Rambaldi A,Barbui T

    更新日期:1993-05-01 00:00:00

  • Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.

    abstract::Tyrosine kinase inhibitors (TKIs) are teratogenic. Chronic myeloid leukemia (CML) is increasingly identified in younger patients who wish to conceive, the management of CML during pregnancy is challenging. We reviewed 51 pregnancies involving 37 patients (30 women, 10 with >1 pregnancy and 7 men) who were either diagn...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1849672

    authors: Assi R,Kantarjian H,Keating M,Pemmaraju N,Verstovsek S,Garcia-Manero G,Ravandi F,Borthakur G,Dahl J,Jabbour E,Cortes JE

    更新日期:2020-12-07 00:00:00

  • Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group.

    abstract::In 90 splenectomized patients with active HCL, this multi-institutional intergroup study showed that as compared to alpha interferon (aIF), pentostatin resulted in a higher incidence of response, but the difference was not statistically significantly. Pentostatin-induced remissions occurred significantly faster and su...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Rai KR

    更新日期:1994-01-01 00:00:00

  • Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.

    abstract::A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.981175

    authors: Kaeda J,Ringel F,Oberender C,Mills K,Quintarelli C,Pane F,Koschmieder S,Slany R,Schwarzer R,Saglio G,Hemmati P,van Lessen A,Amini L,Gresse M,Vagge E,Burmeister T,Serra A,Carson A,Schwarz M,Westermann J,Jundt F,D

    更新日期:2015-07-01 00:00:00

  • Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway.

    abstract::MDSCs, which are defined as a kind of negatively regulatory cells, could suppress T cell immune response in many tumor-bearing animal models and cancer patients. We supposed that MDSCs also contributed to the impaired antitumor immunity in MDS. Here we demonstrated that STAT3-ARG1 pathway could be a critical signal tr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1817431

    authors: Qi X,Jiang H,Liu P,Xie N,Fu R,Wang H,Liu C,Zhang T,Wang H,Shao Z

    更新日期:2021-01-01 00:00:00

  • Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.

    abstract::Rituximab is widely used for CD20+ non-Hodgkin lymphoma (NHL). The use of rituximab has been uncommonly associated with pulmonary toxicity. We report here a single institution experience on the clinical characteristics, diagnosis, treatment and outcome of rituximab-induced interstitial lung disease. From May 2007 to F...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802270886

    authors: Liu X,Hong XN,Gu YJ,Wang BY,Luo ZG,Cao J

    更新日期:2008-09-01 00:00:00

  • Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese superoxide dismutase.

    abstract::The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant sele...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.944521

    authors: Reinke EN,Bera S,Diamond AM

    更新日期:2015-04-01 00:00:00

  • Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.

    abstract::The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.603444

    authors: Markova J,Kahraman D,Kobe C,Skopalova M,Mocikova H,Klaskova K,Dedeckova K,Eich HT,Böll B,Dietlein M,Kozak T

    更新日期:2012-01-01 00:00:00

  • Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

    abstract::BCL6 is a transcriptional repressor often expressed constitutively in diffuse large B-cell lymphomas (DLBCL) due to mutations of its genomic locus. BCL6 mediates aberrant survival, proliferation, genomic instability and differentiation blockade in DLBCL cells. The biochemical study of BCL6 mediated gene repression has...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190801895345

    authors: Parekh S,Privé G,Melnick A

    更新日期:2008-05-01 00:00:00

  • Cytokine receptor gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation.

    abstract::Interleukin-1 receptor type 1 (IL-1R), IL-2 receptor alpha subunit (IL-2R) and IL-6 receptor alpha subunit (IL-6R) mRNA expression in peripheral blood mononuclear cells (PBMC) in 17 patients who underwent allogeneic bone marrow transplantation (allo BMT) and 2 patients who underwent autologous transplantation were ana...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509107899

    authors: Tanaka J,Imamura M,Kasai M,Zhu X,Kobayashi S,Hashino S,Higa T,Sakurada K,Asaka M

    更新日期:1995-10-01 00:00:00

  • Invasive fungal sinusitis: an effective combined treatment in five haematological patients.

    abstract::Invasive fungal rhinosinusitis (IFR) is a life-threatening infection. Its onset is subtle and a late diagnosis leads to severe complications. Death may occur within a few weeks notwithstanding treatment. We describe a comprehensive pre- and post-operative approach to care for haematological patients with IFR. Five hae...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701457923

    authors: Vener C,Carrabba M,Fracchiolla NS,Costa A,Fabio G,Hu C,Sina C,Guastella C,Pignataro L,Deliliers GL

    更新日期:2007-08-01 00:00:00

  • Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia.

    abstract::Fas (APO-1/CD95) consists mainly of 2 isoforms, membrane-anchored (mFas) and soluble (sFas), both of which can mediate apoptosis through the Fas-signalling process, not only in normal but also in leukemia T-cells. This suggests that aberrant expression of either mFas or sFas may affect the natural history of T-cell ne...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057967

    authors: Kamihira S,Yamada Y

    更新日期:2001-03-01 00:00:00

  • Myasthenia gravis and lymphoblastic lymphoma involving the thymus: a rare association.

    abstract::Myasthenia gravis (MG) is an autoimmune neuromuscular junction disease. An association between thymic epithelial neoplasms and MG is well known. However, it is rarely associated with hematologic malignancies. In particular, very few cases of lymphoblastic lymphoma involving the thymus and MG have been reported. Here w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109064612

    authors: Uner AH,Abali H,Engin H,Akyol A,Ruacan S,Tan E,Güllü I,Altundağ K,Güler N

    更新日期:2001-07-01 00:00:00

  • Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.

    abstract::The combination of mitoxantrone (MIT), etoposide (ETP), and cytarabine (Ara-C) (MEC) is a frequently used salvage therapy for acute leukemia, but has been associated with severe myelosuppression. Therefore, we investigated the miniMEC regimen with reduced doses of AraC and MIT. Thirteen ALL and 44 AML patients, all re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1153087

    authors: Yamamoto C,Ito S,Mashima K,Umino K,Minakata D,Yamasaki R,Kawasaki Y,Sugimoto M,Nakano H,Ashizawa M,Okazuka K,Hatano K,Sato K,Oh I,Fujiwara S,Ohmine K,Suzuki T,Muroi K,Kanda Y

    更新日期:2016-11-01 00:00:00